Related Experiment Video
Updated: Jul 4, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Systemic Inflammatory Indices Predict Survival and Limb Outcomes after Revascularization for Chronic Limb-Threatening
Franco Imbrognio1, Ignacio Pepe1, Alfredo Verastegui2
1Saavedra Campus, Instituto Universitario CEMIC, Buenos Aires, Argentina.
Insights
The Systemic Immune-Inflammation Index (SII) can predict survival in chronic limb ischemia patients after revascularization. Lower SII levels correlate with better long-term survival, aiding risk assessment for these high-risk patients.
Area of Science:
- Vascular Surgery
- Cardiology
- Inflammation Biomarkers
Background:
- Chronic limb-threatening ischemia (CLTI) has high mortality and limited risk stratification tools post-revascularization.
- Systemic Immune-Inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI) are emerging prognostic markers.
Purpose of the Study:
- To evaluate the predictive value of SII and SIRI in CLTI patients undergoing revascularization.
- To assess the association of these indices with survival and adverse events.
Main Methods:
- Retrospective single-center cohort study of 122 CLTI patients (endovascular angioplasty or surgical bypass).
- Pre-procedural calculation of SII and SIRI from blood counts.
- Analysis of overall survival, MACE/MALE, and amputation using Kaplan-Meier and Cox regression.
Main Results:
- Surgical bypass showed longer survival than angioplasty (48 vs. 27 months).
- Lowest SII quartile (<492) had significantly better 84-month survival (88.4% vs. 55.1%).
- Elevated SII independently predicted mortality; SIRI was associated with adverse events but not independently.
Conclusions:
- Pre-procedural SII is an independent predictor of survival in CLTI patients post-revascularization.
- SII may serve as a valuable tool for risk stratification in CLTI management.
Introduction:
Chronic limb-threatening ischemia (CLTI) carries high morbidity and mortality, yet risk stratification tools after revascularization remain limited. The Systemic Immune-Inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI) have emerged as prognostic markers. This study evaluated their predictive value in CLTI patients undergoing revascularization.
Methods:
This retrospective single-center cohort study included 122 CLTI patients undergoing endovascular angioplasty (n = 81) or surgical bypass (n = 41) between 2017 and 2023. Pre-procedural SII and SIRI were calculated from blood counts. Outcomes included: overall survival, major adverse cardiovascular and limb events (MACE/MALE), and limb amputation. Kaplan-Meier analysis, Cox regression with Firth's penalized likelihood adjustment, and C-index analyses were performed.
Results:
Surgical bypass was associated with longer median survival than angioplasty (48 vs. 27 months, p = 0.012). Patients in the lowest SII quartile (<492) had significantly improved 84-month survival versus higher quartiles (88.4% vs. 55.1%). Elevated SII remained independently associated with mortality on multivariable analysis. SIRI was higher among patients with adverse events (2.7 vs. 2.0, p = 0.024) but was not independently associated with outcomes. SII demonstrated moderate-to-high predictive performance, with C-indices up to 0.921 in the bypass subgroup.
Conclusion:
Pre-procedural SII is independently associated with survival following CLTI revascularization and may aid risk stratification.
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above the...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
